Thrombophilia

Antithrombin (AT)*
Protein C (PC)*
Protein S (PS)*
Factor V Leiden*
Protein Z (PZ)
Lupus Anticoagulant (LA)*
Other Autoantibodies
Phospholipid Binding Proteins
Blood Activation Biomarkers
Activated Factors

Spontaneous thromboembolic diseases are observed in presence of congenital or acquired deficiencies of antithrombin. These deficiencies are classified in 4 different groups:
   • Type I: Decreased AT concentration and decreased AT activity; this is the most frequent case.
   • Type II RS (Reactive Site): Normal AT concentration and decreased biological activity; a protein abnormality is present at the active site.
   • Type II HBS (Heparin Binding Site): Normal AT concentration, normal AT activity in the absence of heparin, but decreased in its presence.
   • Type II (Pleiotropic): Decreased AT concentration and activity; nonfunctional protein and at a lowered level.

 

* cf Dedicated instructions for use

 

Assay of coagulation PC in plasma helps for the diagnosis of congenital or acquired PC deficiencies.
Acquired deficiencies are observed in hepatic diseases, during VKA therapy or in Disseminated Intravascular Coagulation (DIC).
Congenital deficiencies can be quantitative (Type I) or qualitative (Type II) and are associated with recurrent venous thromboses.
Congenital or acquired PC deficiency is a risk factor for venous thrombosis.

 

* cf Dedicated instructions for use

 

Congenital or acquired PS deficiencies are associated with an increased risk of venous thromboembolism.
In the early stages of inflammatory diseases, free PS concentration is decreased because of an elevation of C4b-BP. PS may be decreased in various contexts such as dicoumarol or L-asparaginase therapy, in hepatic disorders, nephrotic syndrome, during pregnancy, related to oral contraceptives intake or œstrogen therapy, viral infections, DIC. Free PS may also be decreased in new-borns. PS is slightly lower in females than in males.
Inherited PS deficiencies are classified into three types:
   • Type I: decreased total and free PS levels (quantitative defects).
   • Type II: decreased PS activity but normal antigenic levels (rare qualitative defects).
   • Type III: normal levels of total PS but decreased free PS (free form distribution defect).

 

* cf Dedicated instructions for use

 

Factor V Leiden (FV-L) mutation is the most common hereditary thrombophilia risk factor. Patients carrying FV-L mutation have an increased risk of venous thrombosis.
This genetic anomaly can be evidenced with clotting assays, performed in presence or absence of APC.

 

* cf Dedicated instructions for use

 

   

 

LA are associated with numerous clinical states including e.g. lupus, autoimmune diseases, thrombosis, fœtal loss and must usually be confirmed from multiple assays.

 

* cf Dedicated instructions for use

 
CEPHEN™
HEMOCLOT™
Anti-Cardiolipin / Anti phospholipid Antibodies
Anti-β2GP1 Autoantibodies

   

 

   

 

   

 

   

 
Factor XIa (FXIa)
Factor IXa (FIXa)
Factor VIIa (FVIIa)